This approach exploits the following two complementary mechanisms: PARP inhibitors create DNA damage and activate innate immune sensing via cGAS-STING, while PD-1/PD-L1 blockade restores T cell-mediated cytotoxicity in an increasingly inflamed tumor microenvironment. Here, PDCD1 is linked to neoplasm.